100 related articles for article (PubMed ID: 23757446)
1. Immunoinflammatory responses in gastrointestinal tract injury and recovery.
Verma G; Marella A; Shaquiquzzaman M; Alam MM
Acta Biochim Pol; 2013; 60(2):143-9. PubMed ID: 23757446
[TBL] [Abstract][Full Text] [Related]
2. Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins.
Brzozowski T; Konturek PC; Pajdo R; Ptak-Belowska A; Kwiecien S; Pawlik M; Drozdowicz D; Sliwowski Z; Brzozowski B; Konturek SJ; Pawlik WW
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():89-102. PubMed ID: 18812631
[TBL] [Abstract][Full Text] [Related]
3. Gastroduodenal mucosal defense.
Dong MH; Kaunitz JD
Curr Opin Gastroenterol; 2006 Nov; 22(6):599-606. PubMed ID: 17053436
[TBL] [Abstract][Full Text] [Related]
4. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
[TBL] [Abstract][Full Text] [Related]
5. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution.
Serhan CN
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):141-62. PubMed ID: 16005201
[TBL] [Abstract][Full Text] [Related]
6. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation.
Wallace JL
ScientificWorldJournal; 2006 May; 6():577-88. PubMed ID: 16752007
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress in inflammation-based gastrointestinal tract diseases: challenges and opportunities.
Kim YJ; Kim EH; Hahm KB
J Gastroenterol Hepatol; 2012 Jun; 27(6):1004-10. PubMed ID: 22413852
[TBL] [Abstract][Full Text] [Related]
8. Mediators of inflammation: production and implication in inflammatory bowel disease.
Kolios G; Petoumenos C; Nakos A
Hepatogastroenterology; 1998; 45(23):1601-9. PubMed ID: 9840114
[TBL] [Abstract][Full Text] [Related]
9. [Progress in study for mechanism of gastric mucosal injury].
Yoshida N
Nihon Rinsho; 2001 Sep; 59(9):1829-36. PubMed ID: 11554060
[TBL] [Abstract][Full Text] [Related]
10. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin.
Gilroy DW
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):203-10. PubMed ID: 15978791
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress, nitric oxide and prostaglandin E2 levels in the gastrointestinal tract of aging rats.
Mármol F; Sánchez J; López D; Martínez N; Mitjavila MT; Puig-Parellada P
J Pharm Pharmacol; 2009 Feb; 61(2):201-6. PubMed ID: 19178767
[TBL] [Abstract][Full Text] [Related]
12. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases.
Lee IT; Yang CM
Biochem Pharmacol; 2012 Sep; 84(5):581-90. PubMed ID: 22587816
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
Coruzzi G; Venturi N; Spaggiari S
Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury.
Cuzzocrea S; Riley DP; Caputi AP; Salvemini D
Pharmacol Rev; 2001 Mar; 53(1):135-59. PubMed ID: 11171943
[TBL] [Abstract][Full Text] [Related]
15. [Free radicals and antioxidants: physiology, human pathology and therapeutic aspects (part II)].
Sahnoun Z; Jamoussi K; Zeghal KM
Therapie; 1998; 53(4):315-39. PubMed ID: 9806002
[TBL] [Abstract][Full Text] [Related]
16. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.
; Wilcox CM; Allison J; Benzuly K; Borum M; Cryer B; Grosser T; Hunt R; Ladabaum U; Lanas A; Paulus H; Regueiro C; Sandler RS; Simon L
Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1082-9. PubMed ID: 16877048
[No Abstract] [Full Text] [Related]
17. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
Sostres C; Gargallo CJ; Arroyo MT; Lanas A
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):121-32. PubMed ID: 20227026
[TBL] [Abstract][Full Text] [Related]
18. Inflammation and cancer: an epidemiological perspective.
Thun MJ; Henley SJ; Gansler T
Novartis Found Symp; 2004; 256():6-21; discussion 22-8, 49-52, 266-9. PubMed ID: 15027481
[TBL] [Abstract][Full Text] [Related]
19. Recent role of inflammation in prostate diseases: chemoprevention development opportunity.
Hamid AR; Umbas R; Mochtar CA
Acta Med Indones; 2011 Jan; 43(1):59-65. PubMed ID: 21339547
[TBL] [Abstract][Full Text] [Related]
20. Chronic inflammation and cancer.
Shacter E; Weitzman SA
Oncology (Williston Park); 2002 Feb; 16(2):217-26, 229; discussion 230-2. PubMed ID: 11866137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
